Guidance, tools, and resources for evidence-based decisions on vaccine switches and EPI portfolio optimization

Countries now have access to an unprecedented wave of new vaccine presentation and product options and alternative schedules, with more options in the pipeline. This expanding landscape provides an opportunity for countries to examine the vaccine portfolio to identify ways to improve coverage and impact, reduce costs and wastage, and lessen the burden on the cold chain and on health workers. Each switch comes with trade-offs — it is crucial that countries assess their priorities and weigh available evidence and programmatic factors for each option.

This website provides links to guidance, resources, and tools to support countries in navigating available options and making evidence-based decisions to optimize the cost, impact, logistics or programmatic ease of their vaccine portfolio. 

Content 

1. Vaccine portfolio optimization guidance
2. Guidance for Gavi-eligible countries
3. Decision-making tools and resources
4. Vaccine-specific information

Vaccine switch type definitions and examples

Switch type	Definition and examples
Product	Change to a vaccine manufactured by a different supplier and/or with a different combination or strain composition  Examples:  - Switch from PCV13 to PCV10   - Switch from PCV10-4 (Synflorix) to PCV10-5 (PNEUMOSIL)
Presentation	Change to a different primary presentation (vial size, blow-fill-seal), formulation (liquid, lyophilised), or delivery technology (pre-filled syringe, patches)  Examples:  - Switch from ROTASIIL lyophilized to ROTASIIL liquid  - Switch from 10-dose vials for MCV to 5-dose vials
Schedule	Change the dose schedule of the same vaccine  Examples:  - Switch from 3+0 schedule for PCV to 2+1 schedule  - Switch from 2-dose HPV vaccine schedule for the target cohort to 1-dose schedule
Use	Change how the same vaccine in the same formulation is administered  Example:  - Switch from administering IPV as an intramuscular injection to administering as a fractional dose intradermal injection

1. Vaccine portfolio optimization guidance

2. Guidance for Gavi-eligible countries

3. Decision-making tools and resources 

Decision support tools and technical assistance 

 

Country experiences and lessons learned

4. Vaccine-specific information

Pneumococcal conjugate vaccines (PCV) 

Rotavirus vaccines (RVV)

Human papillomavirus (HPV) vaccines 

Measles-containing vaccines (MCV / MR / MMR)

Hexavalent Vaccine

Ressources non disponibles.